CaffinePhase 4NCT07466628
Effects of Caffeine Ingestion on Morning Cognitive and Muscle Strength Measures in Males
A Phase 4 study testing No Pill in people with Caffine and Placebo - Control, run by Liverpool John Moores University at 1 site in United Kingdom.
Trial summary
Tournament scheduling and environmental factors often require athletes to compete in the morning. Equally due to time constraints, athletes may choose to train in the morning. However, muscle power output and force production, are higher in the mid-afternoon or early evening whatever the method used, the muscle groups… Read more about this study
- Who is it for?
- Ages 18 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Caffine, Placebo - Control, No Pill
- What is being tested?
- No Pill
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 15 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 15 Nov 2024to 25 Jul 2025
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy adults
- 18-35 years old
- Injury-free
- ≥ 2 years of weight/strength training experience
- Not receiving any pharmacological treatment (including non-steroidal anti-inflammatory drugs, NSAIDs) throughout the study period
- Low habitual caffeine consumers (≤ 150mg per day)
- No preference to training regarding time-of-day
Who cannot join
- Depressed mood (from the Beck depression inventory)
- Poor sleep quality (a Pittsburgh sleep quality index global score >5
- Recent shiftwork or travel across multiple time-zones
- 'Extreme' chronotype (assessed via the Composite Morningness Questionnaire
- Risk factors and/or symptoms of cardiovascular disease.
- Minimal knowledge of the effects of time-of-day or time-since-sleep on human performance
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Tom Reilly Building (LJMU)
Liverpool, Merseyside, L3 3AF
About this study
Official title: Effects of Caffeine Ingestion on Morning Cognitive and Muscle Strength Measures in Males, Where a Standardized Approach Has Been Employed
Tournament scheduling and environmental factors often require athletes to compete in the morning. Equally due to time constraints, athletes may choose to train in the morning. However, muscle power output and force production, are higher in the mid-afternoon or early evening whatever the method used, the muscle groups tested or the mode and speed of contraction. Cognitive performance is another essential determinant for many athletes that has been shown to be time-of-day and variable dependent. Considered as multifactorial, it includes many different components related to attention, accuracy, consistency, reaction time, vigilance, decision making and executive functions. Executive functions notably include the ability to plan and coordinate considered action while updating it with inhibition processes of distractions to focus attention on the relevant information. Subjective negative mood states (fatigue) and motivation levels, which are essential elements for tasks requiring higher cognitive function are poorer in the morning than the evening.
Caffeine (1,3,7-trimethylxanthine) is amongst the most extensively researched ergogenic supplements within the field of sport, aimed at enhancing alertness, concentration, cognitive and physical performance. Caffeine's primary mechanism of action in the brain is the blockage of adenosine receptors, which play a central role in the regulation of sleep-wake-cycle by increasing sleep pressure throughout the activity phase. It is thought that by blocking these receptors, caffeine counteracts natural tiredness, improving attention, focus and improving overall cognitive performance. One of the few studies to investigate caffeine effects on morning cognitive performance report-ed an improvement in a simple search task 2.5 % in undergraduate students, when 4 mg.kg-1 body mass of caffeine was consumed 1-h before a 07:00 h experimental session versus Placebo. Unlike the sparce research investigating cognitive effects of morning caffeine ingestion, its effects on muscle performance have been demonstrated elsewhere. Caffeine (3 mg.kg-1 body mass) ingested 60-min before exercise increased dynamic strength and power output of upper and lower muscle groups in the morning (10:00 h) in resistance-trained men, with 4.6-5.3% improvement compared to placebo. Similarly, caffeine (3 mg.kg-1 body mass) ingested 60-min before exercise at 09:00 h improved muscular strength/power at moderate-to-high loads (75-90% 1RM) and endurance performance (65% 1RM) in the back squat while counteracting morning declines at light-load (25% 1RM) for both back squat and bench press without altering electrical activity. These benefits are likely due to increased neural activation, enhanced calcium release in muscles, and a reduction in the perception of effort during exercise, making it easier to exert maximal effort.
Read more
The observation of caffeine's ability to improve morning cognitive and physical performance, may be obscured by lack of rigor and standardization in the method employed (such as timing of the ingestion and dose chosen). Many studies do not report any control condition that consider a placebo effect (no pill, familiarization of the tests to be conducted, recruit sample size based on a power calculation and no standardization of participants habitual caffeine use (low, medium or high caffeine daily users). In addition, studies have often failed to control important factors such as chronotype, time-of year, or time-of-day and participants' quality of sleep. Which specifically relates to investigations of chronobiological nature and other considerations.
Objectives:
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on morning
- strength and power output measured via the Biodex Isometric MVC as well as the Muscle Lab force-velocity linear encoder [such as peak force (PF), % muscle activation, average power (AP), average velocity (AV), peak velocity (PV), mean propulsive velocity (MPV), rate of development of velocity (RDV), displacement (D) and time-to-peak velocity (tPV)] and b) cognitive performance (including tasks of attention, memory and executive function).
A population of low daily users < 150 mg was chosen, to reduce effects of caffeine withdrawal symptoms on the non-caffeine condition on performance. As well as maximize caffeine effects at the 300 mg dose administered.
Read the detailed description
Participants Fourteen male adults of biological sex and gender who were classified as "recreationally active". All participants were recruited from the University Sport Science department student population. Inclusion criteria were healthy adults (18-30 years), injury-free, with previous weight/strength training experience (≥ 2 years). The project also opened participation to females, but no females volunteered. Participants habitually retired to bed between 22:00-23:30 h and rose at 06:00-07:30 h and for the study purposes agreed to retire at 22:30 and rise at 06:30 h. None of the participants were receiving any pharmacological treatment (including non-steroidal anti-inflammatory drugs, NSAIDs) throughout the study period. Habitual caffeine consumption was assessed using the caffeine consumption questionnaire (CCQ) and those with >150 mg per day were excluded. Further, all participants expressed no preference to training regarding time-of-day by a weekly self-reported 2-week training diary. Recruiting participants with this specific type of exercise history meant that the known neuromuscular facilitative responses, which are typically associated with acute increases in muscular strength amongst untrained individuals due to neural adaptations and responses were reduced. Exclusion criteria included depressed mood (from the Beck depression inventory), poor sleep quality (a Pittsburgh sleep quality index global score >5, recent shiftwork or travel across multiple time-zones and 'extreme' chronotype (assessed via the Compo-site Morningness Questionnaire) and risk factors and/or symptoms of cardiovascular disease. Through interviews, it was established that the volunteers had minimal knowledge of the effects of time-of-day or time-since-sleep on human performance. Verbal explanation of the experimental procedure was provided to everyone; this included the aims of the study; the possible risks associated with participation and the experimental procedures to be utilized. Any questions were answered. Individuals then provided written, informed consent before participating in the study. The experimental procedures were approved by the Human Ethics Committee at Liverpool John Moores University (ETHICS CODE: 08/SPS/030). The study was conducted in accordance with the ethical standards of the journal and complied with the principles of the Declaration of Helsinki.
Research design All participants were required to visit the physiological laboratory (Liverpool, UK) on seven occasions (dry temperature of 19-21°C, 29-41% humidity, barometric pressure of 962-1010 mmHg and ambient light of 750 lux). Participants completed (i) one maximum repetition (1RM) for bench press and back squat, ii) two familiarization sessions of cognitive and strength performance tests one week prior to the experimental protocol. During familiarizations participants completed a 7-day food diary that was analyzed using Nutritics® analysis software by a SENr registered Sports and Exercise Nutritionist. The remaining sessions consisted of iii) three experimental sessions, all at least 72-h apart as a standardized recovery period. The experimental part comprised three experimental trials a) Control (NoPill), b) Caffeine (300 mg, CAFF) and c) placebo (maltodextrin, PLAC)] between 07:30 and 08:30 h (Figure 1). Participants retired the previous night around 22:30 h, woke up at 06:30 h and arrived at the laboratory at 07:00 h in a fasted state. For the CAFF and PLAC conditions, pills were provided in a plastic bottle with instructions to consume with water at 06:30 h prior to arrival at the laboratory, with confirmation upon arrival. For the NoPill control, nothing was provided. Participants were instructed to avoid training or intense physical activity 48 h prior to any of the visits, other-wise, participants maintained their normal daily routines. In total the three caffeine capsules contained 300 mg of caffeine anhydrous and the remaining space was occupied by malto-dextrin (Applied Nutrition LTD, Knowsley, UK) and placebo capsules were made in the department and contained malto-dextrin (~2.4 g, Sport supplements Ltd t/a BulkTM Colchester, UK). Researchers and participants were blinded to the supplement schedule and both caffeine and placebo were lightly dusted with malto-dextrin to create a similar taste, both had similar weight (0.8 g/capsule) and were 00 size. The order for treatment was revealed at the end of the project by a researcher responsible for anonymization and randomization.
All trials were performed with only one participant at a time, but with a staggered start so one participant came in at 06:45, the next 07:00 h and the last for that morning's session at 07:15 h. This scheduling for participants was kept consistent for all sessions. All participants lived no more than 10 mins away from the University laboratories. Participants were equally allocated, based on their 1RM for bench and back squat into three groups (A, B and C), by listing participants' times from the second familiarization in order from the strongest to the weakest and assigning letters A, B and C in order. The incidence of the learning effect was minimized by assigning the experimental conditions in counterbalanced order. The present study was carried out between the months of November to February (UK Autumn to Winter), with morning sunlight exposure limited to <80 Lux before arriving at the laboratory. The sunrise range for the duration of the study was 07:12 to 07:03 h.
Protocol and measurements: familiarization sessions The participants completed two familiarization sessions of all the strength, cognitive and questionnaire measures, before being considered as ready to participate in the study. A coefficient of variation values less than or equal to 10 % for variables between the first and second measures was used as criteria for familiarization in alignment with the recommendations given by Atkinson and Nevill [26]. Familiarization sessions took place at 12:00 h over a three-week period and finished one week before the study commenced to minimize learning effects. Participants arrived 0.5 hours before the start of the test and rested in a seated position, to minimize the influence of prior muscle activity. Participants completed the familiarization in the following order: i) cognitive battery of tests, ii) isometric maximal voluntary contraction (MVC) with and without percutaneous electrical stimulation, iii) back squat and bench press.
- Cognitive battery of tests Trail Making Test (TMT; parts A and B): Both parts of the TMT consist of 25 circles distributed over a sheet of A4 paper. In part A the circles are numbered 1-25, and the participant is instructed to draw lines to connect the numbers in ascending order. In part B, the circles include both numbers (1-13) and letters (A-L) and the participant is in-structed to draw lines to connect the circles in ascending pattern but with the added task of alternating between numbers and letters (i.e., 1-A-2-B-3-C etc.). In both parts the participant is instructed to connect to the circles as fast as possible, without lifting the pencil from the paper. If an error is made, this is pointed out immediately and the participant is allowed to correct it. During the test, time to completion is measured, with a higher time indicative of the greater impairment.
Rey Auditory Verbal Learning Test: The RAVLT is a neuropsychological assessment designed to evaluate verbal memory in patients aged 16 years and older. The RAVLT can be used to evaluate the nature and severity of memory dysfunction and to track changes in memory function over time [28]. The test is designed as a list-learning paradigm in which the volunteer hears a list of 15 nouns and is asked to recall as many words from the list as possible. The number correct and the number that were given by the participant but not on the list (intrusions) are noted. This process is re-peated 4 more times. The process is repeated but with a second "interference" list (List B) is presented in the same manner, and the participant is asked to recall as many words as possible from List B and scoring recorded. After the interference trial, the participant is immediately asked to recall the words from List A, which they heard five times previously and the number of correct words and intrusions are recorded. RAVTL total number, number of distractions and retention are recorded and analysed.
Stroop word-colour interference test. The participants were asked to read out their responses to words or colours for 45 s as quickly as possible and to leave no errors uncorrected. This was filmed and the number of errors and total amount completed was recorded and analysed. The first sheet had text (red, blue, yellow, black and green) in black ink (naming word test, W). The second sheet had blocks of colour corresponding to the text on the first sheet (naming colour test, C). With the third sheet, the participants had to read out the word (which was coloured differently to the word, e.g., the word was yellow and the colour red, referred to as the naming colour of word test, CW) and for the fourth sheet, the participants had to read out the colour (which was wrongly named, e.g., the colour was yellow but the word was red, referred to as the naming of word not colour test, WC). In this fourth sheet, the words were printed in the reverse order to the third sheet. The raw data were analysed for number of errors (to give an indication of pacing/speed accuracy in the 45 s) and interference scores (an indicator of the efficiency of the inhibitory function), where C represents the correct answers produced in 45 s in naming colours, and CW corresponds to the correct answers achieved in 45 s in the interference condition. This was also performed for the naming of word not-colour test.
I = [(C - CW) / (C + CW)] × 100 (1)
ii) Isometric maximal voluntary contraction Participants performed isometric MVCs of the quadriceps muscles (3 s duration), both with and without twitch interpolation percutaneous stimulation (Digimeter, DS7, Hertfordshire, UK). During the initial session, participants practiced performing MVCs without twitch interpolation, to become accustomed to the practice of achieving and maintaining voluntary force for the time required. This session was also used to obtain maximal current tolerance and establish the supra-maximal current amplitude for superimposition during an MVC. With the subject at rest, the amperage of a 240 V square-wave pulse (100 μs, 1 Hz) was progressively increased until the point when further increases in intensity caused no further increase in resting twitch force reached.
Twitch interpolation The quadriceps were electrically stimulated using two moistened surface electrodes (Chattanooga, USA, 5 x 12 cm) which were positioned proximally over the vastus lateralis and distally over the vastus medialis. The skin was pre-pared prior to placement of each electrode by shaving and light abrasion of the skin, followed by cleaning with an iso-propyl alcohol swab. A permanent marking pen was used to mark and identify the position of each electrode to minimize electrode placement variability from session to session. Two impulses were delivered before and after the contractions; the other two impulses were administered during the contraction period and tested the peak value of the MVC. The peak forces of the pre- and post-contraction twitches were then averaged, allowing comparison of resting twitch amplitudes in both an unpotentiated and potentiated condition respectively. The amplitude of supra-maximal superimposed current was identified for each subject in familiarization sessions and corresponded to 10% above the level required to evoke a resting muscle twitch of maximal amplitude.
Data was acquired for nine seconds and analysed with a commercially designed software program (AcqKnowledge III, Biopac Systems, Massachusetts). The calculation of voluntary activation was conducted according to an interpolated twitch ratio whereby the size of the interpolated twitch is ex-pressed as a ratio of the amplitude elicited by the same stimulus delivered to a relaxed potentiated muscle. The average force during the 100 m.s-1 period before the application of each stimulus during the contraction was recorded and subsequently the maximal force recorded during the 100 m.s-1 period after each stimulus had been applied. The 100 m.s-1 mean pre-stimulus force (taken as MVC force) and the resulting maximal post-stimulus force were used to calculate the size of the interpolated twitch, by subtraction of the mean pre-stimulus force from the maximal post-stimulus force.
Voluntary Activation = = [1 - (Size of interpolated twitch / Size of resting twitch)] x 100
During familiarization sessions, participants alternated between performing MVCs with and without twitch interpolation, so that approximately three trials of each were performed within each session. Standardized strong verbal encouragement during each familiarization session/trial and real-time visual feedback of their performance was provided to the participants via the computer display onto a large screen placed in front of them.
iii) Back squat and bench press Participants were familiarized with back squat and bench press three times prior to commencement of the testing cycle. Each participant was asked to perform the back squat with incremental loads (40, 60, 80% 1RM) for one repetition at each load and 5-min rest was allowed between each effort. Likewise for bench press, each participant performed one repetition against each incremental load (40, 60 and 80 % 1RM) and again 5-min rest was given between each working effort. This was done so that the upper loads required for the experimental trials were known to be comfortably within each of the participants' physical capabilities and as such there was minimal likelihood of them failing to perform the required efforts for data collection. Each of the participants performed the two exercises in same order: bench press and then back squat, performing three lifts at each exercise against progressively increasing loads (40, 60 and 80 % 1RM). The individual's own body mass was factored into the back squat exercise, as this is a whole-body movement, but not into the bench press. The MuscleLab force-velocity linear encoder (Muscle Lab, Ergotest version 4010, Norway) was attached to an Eleiko Olympic bar (20 kg) which was set upon rests on a standard squat rack, safety arms were set so that the participant achieved ≤90° knee flexion position (settings measured and recorded during the familiarization process). From this position, the participant was instructed to drive the bar upwards as forcefully as possible; the value recorded during the test was for the concentric phase of the action only. The MuscleLab system encodes the force, the displacement of the bar, and the velocity produced for each individual lift, so that following measurements of muscle performance can be measured: average velocity (AV), average power (AP, average force x average velocity), peak velocity (PV, highest value of velocity), time to peak velocity (tPV, time to reach the highest value of velocity), mean propulsive velocity (MPV, average velocity during the propulsive phase of the concentric movement), rate of development of velocity (RDV, average acceleration during the propulsive phase of the concentric movement) and displacement (D, linear dis-placement of the bar during the movement). This process was repeated three times, with 5-min rest allowed between each individual lift, and against the progressive workloads as described above. For the bench press, the participant was instructed to descend the bar to their chest and, again, the instruction given was to push against the bar as forcefully as possible. This was repeated three times against the workloads described above, with 5-min rest between each push.
The highest of the three AP outputs (and associated AV, PV, MPV, RDV, D and tPV values) were used for analysis for each mass on the bar for both bench press and back squat, respectively. To reduce the likelihood of injury, two people were positioned either side of the participants as they performed their lifts, to intervene at any time if needed. In addition, there was safety support in place on every occasion.
Experimental Protocol and Measurements
The experimental sessions took place a week after the last familiarization with 72 h recovery between the three experimental conditions (i.e. CAFF, PLAC, NoPill). Upon arrival at the laboratory, they were asked to insert a soft flexi-ble rectal probe (mini-thermistor, Grant Instruments, Shepreth, UK) approximately 10 cm beyond the external anal sphincter. Participants then rested for 30 min in seated position to assess resting rectal temperature (Trec). Skin temperature (Tsk) was assessed simultaneously by skin thermistors (Grant Instruments, Squirrel 2010 series, Shepreth, UK), which were placed at four locations on the left side of the body (chest [ch], forearm [f], thigh [th] and calf [ca]). The average of the last 5 min of the 30 min resting period was recorded for resting Trec and Tsk temperatures. Mean Tsk was calculated as follows:
Tsk = (0.34 x Tch) + (0.33 x Tth) + (0.18 x Tca) + (0.15 x Tf)
The mean body temperature (Tmb) was calculated using:
Tmb = (0.64 x Tr) + (0.36 x Tsk).
Participants completed profile of mood states questionnaire (POMS; Version 32), their subjective rating of sleep (using sleep questions from the Liverpool Jet lag Questionnaire, effort (0-10, 0 = no effort and 10 = maximal effort) and rating of perceived exertion (RPE). After the initial rest measurements, participants warmed up on a cycle ergometer (Corival cpet, Lode, Groningen, Netherlands) for 5 min at 150 W. Post warm-up, participants removed rectal probes in private and skin thermistors were taken off. After which, MVC and bench press and back squat exercises were then undertaken.
Statistical analysis The main research variables in the present study were peak force in the MVC and PV in the bench press and back squat. For MVC peak force sixteen participants were estimated to provide 80% statistical power (p < 0.05), diurnal variation effect size (ES) of 0.67 for one tailed t-test. For PV for bench press nine participants were estimated to provide 80% statistical power (p < 0.05), diurnal variation effect size (ES) of 0.92 for one tailed t-test. For PV for back squat nine participants were estimated to provide 80% statistical power (p < 0.05), diurnal variation effect size (ES) of 0.91 for one tailed t-test. The investigators recruited 18 participants to allow for a dropout, with n=4 unable to complete the full protocol. The sample size estimation was performed using software G*Power 3.1. Data were analysed using the Statistical Package for Social Sciences version 30 (SPSS, Chicago, IL, USA). All data were checked for normality using the Shapiro-Wilk test. General linear models were used to analyse all measurements collected; the significance of interactions and main effects were evaluated by ANOVA. Sphericity violations were corrected by Greenhouse-Geisser (ε < 0.75) or Huynh-Feldt (ε > 0.75) and main effects by Bonferroni pairwise comparisons. Pearson correlations were conducted to explore individualized responses to CAFF vs other conditions (relative to body mass) and % change in MVC performance. All data is presented as means ± standard deviation (SD), unless otherwise stated. Significance was set at p ≤ 0.05. P values between 0.05 and 0.10 were considered to indicate a statistical trend. Effect sizes are referred to as partial eta squared values (η2p) with values of 0.01, 0.06 and 0.14 corresponding to a small, medium and large effect respectively. Ninety-five percent confidence intervals (95% CI) and mean differences between pairwise comparisons are reported where suitable.
- Conditions
- Caffine, Placebo - Control, No Pill
- Being tested
- 300mg of of caffeine anhydrous in 3 capsules similar to PLACEBO in size and weight, Placebo, No Pill
- Keywords
- Caffine, morning cognitive performance, morning strength performance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
300mg of of caffeine anhydrous in 3 capsules similar to PLACEBO in size and weightDrug
300mg of of caffeine anhydrous in 3 capsules similar to PLACEBO in size and weight
PlaceboOther
Description: 3 capsules of PLACEBO similar to caffeine condition in size and weight
No PillDietary supplement
No capsules were given.
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Experimental | 1) NoPill, 2) PLAC, 3) Caffeine (300 mg) Receives: Drug: 300mg of of caffeine anhydrous in 3 capsules similar to PLACEBO in size and weight; Other: Placebo; Dietary Supplement: No Pill |
| Group 2 | Experimental | 1) PLAC, 2) Caffeine (300 mg), 3) NoPill Receives: Drug: 300mg of of caffeine anhydrous in 3 capsules similar to PLACEBO in size and weight; Other: Placebo; Dietary Supplement: No Pill |
| Group 3 | Experimental | 1) Caffeine (300 mg), 2) NoPill, 3) PLAC Receives: Drug: 300mg of of caffeine anhydrous in 3 capsules similar to PLACEBO in size and weight; Other: Placebo; Dietary Supplement: No Pill |
What is being measured
The primary outcome is the main question the study is designed to answer.
Morning peak force production (N) measured via the Biodex Isometric MVC, with and without percutaneous stimulation.
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on morning peak force production (N) measured via the Biodex Isometric MVC, with and without percutaneous stimulation.
Measured: From familiarisation to the final experimental session (~4 weeks)
Muscle Lab force-velocity linear encoder morning average power (AP, W), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition).
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on Muscle Lab force-velocity linear encoder morning average power (AP, W), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition). The individual's own body mass was factored into the back squat exercise, as this is a whole-body movement, but not into the bench press. The MuscleLab force-velocity linear encoder (Muscle Lab, Ergotest version 4010, Norway) was attached to an Eleiko Olympic bar (20 kg) which was set upon rests on a standard squat rack, safety arms were set so that the participant achieved ≤90° knee flexion position (settings measured and recorded during the familiarization process). From this position, the participant was instructed to drive the bar upwards as forcefully as possible; the value recorded during the test was for the concentric phase of the action only.
Measured: From familiarisation to the final experimental session (~4 weeks)
Morning average velocity (AV, m/s), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition).
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on Muscle Lab force-velocity linear encoder morning average velocity (AV, m/s), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition). The individual's own body mass was factored into the back squat exercise, as this is a whole-body movement, but not into the bench press. The MuscleLab force-velocity linear encoder (Muscle Lab, Ergotest version 4010, Norway) was attached to an Eleiko Olympic bar (20 kg) which was set upon rests on a standard squat rack, safety arms were set so that the participant achieved ≤90° knee flexion position (settings measured and recorded during the familiarization process). From this position, the participant was instructed to drive the bar upwards as forcefully as possible; the value recorded during the test was for the concentric phase of the action only.
Measured: From familiarisation to the final experimental session (~4 weeks)
Morning peak velocity (PV, m/s), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition).
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on Muscle Lab force-velocity linear encoder morning peak velocity (PV, m/s), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition). The individual's own body mass was factored into the back squat exercise, as this is a whole-body movement, but not into the bench press. The MuscleLab force-velocity linear encoder (Muscle Lab, Ergotest version 4010, Norway) was attached to an Eleiko Olympic bar (20 kg) which was set upon rests on a standard squat rack, safety arms were set so that the participant achieved ≤90° knee flexion position (settings measured and recorded during the familiarization process). From this position, the participant was instructed to drive the bar upwards as forcefully as possible; the value recorded during the test was for the concentric phase of the action only.
Measured: From familiarisation to the final experimental session (~4 weeks)
Morning mean propulsive velocity (MPV, m/s), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition).
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on Muscle Lab force-velocity linear encoder morning mean propulsive velocity (MPV, m/s), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition). The individual's own body mass was factored into the back squat exercise, as this is a whole-body movement, but not into the bench press. The MuscleLab force-velocity linear encoder (Muscle Lab, Ergotest version 4010, Norway) was attached to an Eleiko Olympic bar (20 kg) which was set upon rests on a standard squat rack, safety arms were set so that the participant achieved ≤90° knee flexion position (settings measured and recorded during the familiarization process). From this position, the participant was instructed to drive the bar upwards as forcefully as possible; the value recorded during the test was for the concentric phase of the action only.
Measured: From familiarisation to the final experimental session (~4 weeks)
Morning rate of development of velocity (RDV), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition).
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on Muscle Lab force-velocity linear encoder morning rate of development of velocity (RDV), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition). The individual's own body mass was factored into the back squat exercise, as this is a whole-body movement, but not into the bench press. The MuscleLab force-velocity linear encoder (Muscle Lab, Ergotest version 4010, Norway) was attached to an Eleiko Olympic bar (20 kg) which was set upon rests on a standard squat rack, safety arms were set so that the participant achieved ≤90° knee flexion position (settings measured and recorded during the familiarization process). From this position, the participant was instructed to drive the bar upwards as forcefully as possible; the value recorded during the test was for the concentric phase of the action only.
Measured: From familiarisation to the final experimental session (~4 weeks)
Morning displacement (D, cm), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition).
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on Muscle Lab force-velocity linear encoder morning displacement (D, cm), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition). The individual's own body mass was factored into the back squat exercise, as this is a whole-body movement, but not into the bench press. The MuscleLab force-velocity linear encoder (Muscle Lab, Ergotest version 4010, Norway) was attached to an Eleiko Olympic bar (20 kg) which was set upon rests on a standard squat rack, safety arms were set so that the participant achieved ≤90° knee flexion position (settings measured and recorded during the familiarization process). From this position, the participant was instructed to drive the bar upwards as forcefully as possible; the value recorded during the test was for the concentric phase of the action only.
Measured: From familiarisation to the final experimental session (~4 weeks)
Morning time-to-peak velocity (tPV, m/s/s), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition).
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on Muscle Lab force-velocity linear encoder morning time-to-peak velocity (tPV, m/s/s), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition). The individual's own body mass was factored into the back squat exercise, as this is a whole-body movement, but not into the bench press. The MuscleLab force-velocity linear encoder (Muscle Lab, Ergotest version 4010, Norway) was attached to an Eleiko Olympic bar (20 kg) which was set upon rests on a standard squat rack, safety arms were set so that the participant achieved ≤90° knee flexion position (settings measured and recorded during the familiarization process). From this position, the participant was instructed to drive the bar upwards as forcefully as possible; the value recorded during the test was for the concentric phase of the action only.
Measured: From familiarisation to the final experimental session (~4 weeks)
Secondary outcomes (3)
Morning Trail Making Test time to completion in seconds (TMT; parts A and B)
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on morning Trail Making Test time to completion in seconds (TMT; parts A and B). In part A the circles are numbered 1-25, and the participant is instructed to draw lines to connect the numbers in ascending order. In part B, the circles include both numbers (1-13) and letters (A-L) and the participant is instructed to draw lines to connect the circles in ascending pattern but with the added task of alternating between numbers and letters (i.e., 1-A-2-B-3-C etc.). In both parts the participant is instructed to connect to the circles as fast as possible, without lifting the pencil from the paper. If an error is made, this is pointed out immediately and the participant is allowed to correct it. During the test, time to completion is measured, with a higher time indicative of the greater impairment.
Measured: From enrolment to last experimental session (4 weeks)
Morning Rey Auditory Verbal Learning Test
Rey Auditory Verbal Learning Test: The RAVLT is a neuropsychological assessment designed to evaluate verbal memory. The test is designed as a list-learning paradigm in which the volunteer hears a list of 15 nouns and is asked to recall as many words from the list as possible. The number correct and the number that were given by the participant but not on the list (intrusions) are noted. This process is re-peated 4 more times. The process is repeated but with a second interference list (List B) is presented in the same manner, and the participant is asked to recall as many words as possible from List B and scoring recorded. . After the interference trial, the participant is immediately asked to recall the words from List A, which they heard five times previously and the number of correct words and intrusions are recorded. RAVTL total number, number of dis-tractions and retention are recorded and analysed.
Measured: From familiarisation to the final experimental session (~4 weeks)
Morning Stroop word-color interference test
Stroop word-colour interference test. The participants were asked to read out their responses to words or colours for 45 s as quickly as possible and to leave no errors uncorrected. This was filmed and the number of errors and total amount completed was recorded and analysed. The first sheet had text (red, blue, yellow, black and green) in black ink (naming word test, W). The second sheet had blocks of colour corresponding to the text on the first sheet (naming colour test, C). With the third sheet, the participants had to read out the word (which was coloured differently to the word, e.g., the word was yellow and the colour red, referred to as the naming colour of word test, CW) and for the fourth sheet, the participants had to read out the colon (which was wrongly named, e.g., the colour was yellow but the word was red, referred to as the naming of word not colour test, WC). In this fourth sheet, the words were printed in the reverse order to the third sheet.
Measured: From familiarisation to the final experimental session (~4 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2026
- Study start15 Nov 2024
- Primary completion25 Jul 2025
- Study completion25 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for CaffineStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Double blinded counterbalanced design with three conditions
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Liverpool John Moores University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ben J. Edwards, PhD, Liverpool John Moores University
- Investigators
- Ben J Edwards, PHD, Principal investigator, Liverpool John Moores University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07466628
- Sponsor's protocol ID
- 08/SPS/030
- Status last verified
- Mar 2026
- First submitted
- 25 Feb 2026
- Last updated
- 13 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: IPD unavailable due to privacy or ethical restrictions
Publications
Mitchell PJ, Redman JR. Effects of caffeine, time of day and user history on study-related performance. Psychopharmacology (Berl). 1992;109(1-2):121-6. doi: 10.1007/BF02245489.
PubMed 1365645Martins GL, Guilherme JPLF, Ferreira LHB, de Souza-Junior TP, Lancha AH Jr. Caffeine and Exercise Performance: Possible Directions for Definitive Findings. Front Sports Act Living. 2020 Dec 11;2:574854. doi: 10.3389/fspor.2020.574854. eCollection 2020.
PubMed 33345139Munnilari M, Bommasamudram T, Easow J, Tod D, Varamenti E, Edwards BJ, Ravindrakumar A, Gallagher C, Pullinger SA. Diurnal variation in variables related to cognitive performance: a systematic review. Sleep Breath. 2024 Mar;28(1):495-510. doi: 10.1007/s11325-023-02895-0. Epub 2023 Aug 17.
PubMed 37589927Robertson CM, Pullinger SA, Robinson WR, Smith ME, Burniston JG, Edwards BJ. Circadian variation in muscle force output in males using isokinetic, isometric dynamometry: can we observe this in multi-joint movements using the muscleLab force-velocity encoder and are they similar in peak and magnitude? Chronobiol Int. 2024 May;41(5):709-724. doi: 10.1080/07420528.2024.2348011. Epub 2024 May 9.
PubMed 38722075Drust B, Waterhouse J, Atkinson G, Edwards B, Reilly T. Circadian rhythms in sports performance--an update. Chronobiol Int. 2005;22(1):21-44. doi: 10.1081/cbi-200041039.
PubMed 15865319Walsh NP, Halson SL, Sargent C, Roach GD, Nedelec M, Gupta L, Leeder J, Fullagar HH, Coutts AJ, Edwards BJ, Pullinger SA, Robertson CM, Burniston JG, Lastella M, Le Meur Y, Hausswirth C, Bender AM, Grandner MA, Samuels CH. Sleep and the athlete: narrative review and 2021 expert consensus recommendations. Br J Sports Med. 2020 Nov 3:bjsports-2020-102025. doi: 10.1136/bjsports-2020-102025. Online ahead of print.
PubMed 33144349
Study at a glance
From the registry record, last updated by the sponsor on 13 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Caffeine Ingestion on Morning Cognitive and Muscle Strength Measures in Males, Where a Standardized Approach Has Been Employed
- ClinicalTrials.gov ID
- NCT07466628
- Acronym / sponsor ID
- 08/SPS/030
- Conditions
- Caffine, Placebo - Control, No Pill
- Keywords
- Caffine, morning cognitive performance, morning strength performance
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Liverpool John Moores UniversityUniversity, hospital or other
- Study start
- 15 Nov 2024 (actual)
- Primary completion
- 25 Jul 2025 (actual)
- Study completion
- 25 Jul 2025 (actual)
- First posted
- 12 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Tournament scheduling and environmental factors often require athletes to compete in the morning. Equally due to time constraints, athletes may choose to train in the morning. However, muscle power output and force production, are higher in the mid-afternoon or early evening whatever the method used, the muscle groups tested or the mode and speed of contraction. Cognitive performance is another essential determinant for many athletes that has been shown to be time-of-day and variable dependent. Considered as multifactorial, it includes many different components related to attention, accuracy, consistency, reaction time, vigilance, decision making and executive functions. Executive functions notably include the ability to plan and coordinate considered action while updating it with inhibition processes of distractions to focus attention on the relevant information. Subjective negative mood states (fatigue) and motivation levels, which are essential elements for tasks requiring higher cognitive function are poorer in the morning than the evening.
Caffeine (1,3,7-trimethylxanthine) is amongst the most extensively researched ergogenic supplements within the field of sport, aimed at enhancing alertness, concentration, cognitive and physical performance. Caffeine's primary mechanism of action in the brain is the blockage of adenosine receptors, which play a central role in the regulation of sleep-wake-cycle by increasing sleep pressure throughout the activity phase. It is thought that by blocking these receptors, caffeine counteracts natural tiredness, improving attention, focus and improving overall cognitive performance. One of the few studies to investigate caffeine effects on morning cognitive performance report-ed an improvement in a simple search task 2.5 % in undergraduate students, when 4 mg.kg-1 body mass of caffeine was consumed 1-h before a 07:00 h experimental session versus Placebo. Unlike the sparce research investigating cognitive effects of morning caffeine ingestion, its effects on muscle performance have been demonstrated elsewhere. Caffeine (3 mg.kg-1 body mass) ingested 60-min before exercise increased dynamic strength and power output of upper and lower muscle groups in the morning (10:00 h) in resistance-trained men, with 4.6-5.3% improvement compared to placebo. Similarly, caffeine (3 mg.kg-1 body mass) ingested 60-min before exercise at 09:00 h improved muscular strength/power at moderate-to-high loads (75-90% 1RM) and endurance performance (65% 1RM) in the back squat while counteracting morning declines at light-load (25% 1RM) for both back squat and bench press without altering electrical activity. These benefits are likely due to increased neural activation, enhanced calcium release in muscles, and a reduction in the perception of effort during exercise, making it easier to exert maximal effort.
The observation of caffeine's ability to improve morning cognitive and physical performance, may be obscured by lack of rigor and standardization in the method employed (such as timing of the ingestion and dose chosen). Many studies do not report any control condition that consider a placebo effect (no pill, familiarization of the tests to be conducted, recruit sample size based on a power calculation and no standardization of participants habitual caffeine use (low, medium or high caffeine daily users). In addition, studies have often failed to control important factors such as chronotype, time-of year, or time-of-day and participants' quality of sleep. Which specifically relates to investigations of chronobiological nature and other considerations.
Objectives:
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on morning
- strength and power output measured via the Biodex Isometric MVC as well as the Muscle Lab force-velocity linear encoder [such as peak force (PF), % muscle activation, average power (AP), average velocity (AV), peak velocity (PV), mean propulsive velocity (MPV), rate of development of velocity (RDV), displacement (D) and time-to-peak velocity (tPV)] and b) cognitive performance (including tasks of attention, memory and executive function).
A population of low daily users < 150 mg was chosen, to reduce effects of caffeine withdrawal symptoms on the non-caffeine condition on performance. As well as maximize caffeine effects at the 300 mg dose administered.
Detailed description
Participants Fourteen male adults of biological sex and gender who were classified as "recreationally active". All participants were recruited from the University Sport Science department student population. Inclusion criteria were healthy adults (18-30 years), injury-free, with previous weight/strength training experience (≥ 2 years). The project also opened participation to females, but no females volunteered. Participants habitually retired to bed between 22:00-23:30 h and rose at 06:00-07:30 h and for the study purposes agreed to retire at 22:30 and rise at 06:30 h. None of the participants were receiving any pharmacological treatment (including non-steroidal anti-inflammatory drugs, NSAIDs) throughout the study period. Habitual caffeine consumption was assessed using the caffeine consumption questionnaire (CCQ) and those with >150 mg per day were excluded. Further, all participants expressed no preference to training regarding time-of-day by a weekly self-reported 2-week training diary. Recruiting participants with this specific type of exercise history meant that the known neuromuscular facilitative responses, which are typically associated with acute increases in muscular strength amongst untrained individuals due to neural adaptations and responses were reduced. Exclusion criteria included depressed mood (from the Beck depression inventory), poor sleep quality (a Pittsburgh sleep quality index global score >5, recent shiftwork or travel across multiple time-zones and 'extreme' chronotype (assessed via the Compo-site Morningness Questionnaire) and risk factors and/or symptoms of cardiovascular disease. Through interviews, it was established that the volunteers had minimal knowledge of the effects of time-of-day or time-since-sleep on human performance. Verbal explanation of the experimental procedure was provided to everyone; this included the aims of the study; the possible risks associated with participation and the experimental procedures to be utilized. Any questions were answered. Individuals then provided written, informed consent before participating in the study. The experimental procedures were approved by the Human Ethics Committee at Liverpool John Moores University (ETHICS CODE: 08/SPS/030). The study was conducted in accordance with the ethical standards of the journal and complied with the principles of the Declaration of Helsinki.
Research design All participants were required to visit the physiological laboratory (Liverpool, UK) on seven occasions (dry temperature of 19-21°C, 29-41% humidity, barometric pressure of 962-1010 mmHg and ambient light of 750 lux). Participants completed (i) one maximum repetition (1RM) for bench press and back squat, ii) two familiarization sessions of cognitive and strength performance tests one week prior to the experimental protocol. During familiarizations participants completed a 7-day food diary that was analyzed using Nutritics® analysis software by a SENr registered Sports and Exercise Nutritionist. The remaining sessions consisted of iii) three experimental sessions, all at least 72-h apart as a standardized recovery period. The experimental part comprised three experimental trials a) Control (NoPill), b) Caffeine (300 mg, CAFF) and c) placebo (maltodextrin, PLAC)] between 07:30 and 08:30 h (Figure 1). Participants retired the previous night around 22:30 h, woke up at 06:30 h and arrived at the laboratory at 07:00 h in a fasted state. For the CAFF and PLAC conditions, pills were provided in a plastic bottle with instructions to consume with water at 06:30 h prior to arrival at the laboratory, with confirmation upon arrival. For the NoPill control, nothing was provided. Participants were instructed to avoid training or intense physical activity 48 h prior to any of the visits, other-wise, participants maintained their normal daily routines. In total the three caffeine capsules contained 300 mg of caffeine anhydrous and the remaining space was occupied by malto-dextrin (Applied Nutrition LTD, Knowsley, UK) and placebo capsules were made in the department and contained malto-dextrin (~2.4 g, Sport supplements Ltd t/a BulkTM Colchester, UK). Researchers and participants were blinded to the supplement schedule and both caffeine and placebo were lightly dusted with malto-dextrin to create a similar taste, both had similar weight (0.8 g/capsule) and were 00 size. The order for treatment was revealed at the end of the project by a researcher responsible for anonymization and randomization.
All trials were performed with only one participant at a time, but with a staggered start so one participant came in at 06:45, the next 07:00 h and the last for that morning's session at 07:15 h. This scheduling for participants was kept consistent for all sessions. All participants lived no more than 10 mins away from the University laboratories. Participants were equally allocated, based on their 1RM for bench and back squat into three groups (A, B and C), by listing participants' times from the second familiarization in order from the strongest to the weakest and assigning letters A, B and C in order. The incidence of the learning effect was minimized by assigning the experimental conditions in counterbalanced order. The present study was carried out between the months of November to February (UK Autumn to Winter), with morning sunlight exposure limited to <80 Lux before arriving at the laboratory. The sunrise range for the duration of the study was 07:12 to 07:03 h.
Protocol and measurements: familiarization sessions The participants completed two familiarization sessions of all the strength, cognitive and questionnaire measures, before being considered as ready to participate in the study. A coefficient of variation values less than or equal to 10 % for variables between the first and second measures was used as criteria for familiarization in alignment with the recommendations given by Atkinson and Nevill [26]. Familiarization sessions took place at 12:00 h over a three-week period and finished one week before the study commenced to minimize learning effects. Participants arrived 0.5 hours before the start of the test and rested in a seated position, to minimize the influence of prior muscle activity. Participants completed the familiarization in the following order: i) cognitive battery of tests, ii) isometric maximal voluntary contraction (MVC) with and without percutaneous electrical stimulation, iii) back squat and bench press.
- Cognitive battery of tests Trail Making Test (TMT; parts A and B): Both parts of the TMT consist of 25 circles distributed over a sheet of A4 paper. In part A the circles are numbered 1-25, and the participant is instructed to draw lines to connect the numbers in ascending order. In part B, the circles include both numbers (1-13) and letters (A-L) and the participant is in-structed to draw lines to connect the circles in ascending pattern but with the added task of alternating between numbers and letters (i.e., 1-A-2-B-3-C etc.). In both parts the participant is instructed to connect to the circles as fast as possible, without lifting the pencil from the paper. If an error is made, this is pointed out immediately and the participant is allowed to correct it. During the test, time to completion is measured, with a higher time indicative of the greater impairment.
Rey Auditory Verbal Learning Test: The RAVLT is a neuropsychological assessment designed to evaluate verbal memory in patients aged 16 years and older. The RAVLT can be used to evaluate the nature and severity of memory dysfunction and to track changes in memory function over time [28]. The test is designed as a list-learning paradigm in which the volunteer hears a list of 15 nouns and is asked to recall as many words from the list as possible. The number correct and the number that were given by the participant but not on the list (intrusions) are noted. This process is re-peated 4 more times. The process is repeated but with a second "interference" list (List B) is presented in the same manner, and the participant is asked to recall as many words as possible from List B and scoring recorded. After the interference trial, the participant is immediately asked to recall the words from List A, which they heard five times previously and the number of correct words and intrusions are recorded. RAVTL total number, number of distractions and retention are recorded and analysed.
Stroop word-colour interference test. The participants were asked to read out their responses to words or colours for 45 s as quickly as possible and to leave no errors uncorrected. This was filmed and the number of errors and total amount completed was recorded and analysed. The first sheet had text (red, blue, yellow, black and green) in black ink (naming word test, W). The second sheet had blocks of colour corresponding to the text on the first sheet (naming colour test, C). With the third sheet, the participants had to read out the word (which was coloured differently to the word, e.g., the word was yellow and the colour red, referred to as the naming colour of word test, CW) and for the fourth sheet, the participants had to read out the colour (which was wrongly named, e.g., the colour was yellow but the word was red, referred to as the naming of word not colour test, WC). In this fourth sheet, the words were printed in the reverse order to the third sheet. The raw data were analysed for number of errors (to give an indication of pacing/speed accuracy in the 45 s) and interference scores (an indicator of the efficiency of the inhibitory function), where C represents the correct answers produced in 45 s in naming colours, and CW corresponds to the correct answers achieved in 45 s in the interference condition. This was also performed for the naming of word not-colour test.
I = [(C - CW) / (C + CW)] × 100 (1)
ii) Isometric maximal voluntary contraction Participants performed isometric MVCs of the quadriceps muscles (3 s duration), both with and without twitch interpolation percutaneous stimulation (Digimeter, DS7, Hertfordshire, UK). During the initial session, participants practiced performing MVCs without twitch interpolation, to become accustomed to the practice of achieving and maintaining voluntary force for the time required. This session was also used to obtain maximal current tolerance and establish the supra-maximal current amplitude for superimposition during an MVC. With the subject at rest, the amperage of a 240 V square-wave pulse (100 μs, 1 Hz) was progressively increased until the point when further increases in intensity caused no further increase in resting twitch force reached.
Twitch interpolation The quadriceps were electrically stimulated using two moistened surface electrodes (Chattanooga, USA, 5 x 12 cm) which were positioned proximally over the vastus lateralis and distally over the vastus medialis. The skin was pre-pared prior to placement of each electrode by shaving and light abrasion of the skin, followed by cleaning with an iso-propyl alcohol swab. A permanent marking pen was used to mark and identify the position of each electrode to minimize electrode placement variability from session to session. Two impulses were delivered before and after the contractions; the other two impulses were administered during the contraction period and tested the peak value of the MVC. The peak forces of the pre- and post-contraction twitches were then averaged, allowing comparison of resting twitch amplitudes in both an unpotentiated and potentiated condition respectively. The amplitude of supra-maximal superimposed current was identified for each subject in familiarization sessions and corresponded to 10% above the level required to evoke a resting muscle twitch of maximal amplitude.
Data was acquired for nine seconds and analysed with a commercially designed software program (AcqKnowledge III, Biopac Systems, Massachusetts). The calculation of voluntary activation was conducted according to an interpolated twitch ratio whereby the size of the interpolated twitch is ex-pressed as a ratio of the amplitude elicited by the same stimulus delivered to a relaxed potentiated muscle. The average force during the 100 m.s-1 period before the application of each stimulus during the contraction was recorded and subsequently the maximal force recorded during the 100 m.s-1 period after each stimulus had been applied. The 100 m.s-1 mean pre-stimulus force (taken as MVC force) and the resulting maximal post-stimulus force were used to calculate the size of the interpolated twitch, by subtraction of the mean pre-stimulus force from the maximal post-stimulus force.
Voluntary Activation = = [1 - (Size of interpolated twitch / Size of resting twitch)] x 100
During familiarization sessions, participants alternated between performing MVCs with and without twitch interpolation, so that approximately three trials of each were performed within each session. Standardized strong verbal encouragement during each familiarization session/trial and real-time visual feedback of their performance was provided to the participants via the computer display onto a large screen placed in front of them.
iii) Back squat and bench press Participants were familiarized with back squat and bench press three times prior to commencement of the testing cycle. Each participant was asked to perform the back squat with incremental loads (40, 60, 80% 1RM) for one repetition at each load and 5-min rest was allowed between each effort. Likewise for bench press, each participant performed one repetition against each incremental load (40, 60 and 80 % 1RM) and again 5-min rest was given between each working effort. This was done so that the upper loads required for the experimental trials were known to be comfortably within each of the participants' physical capabilities and as such there was minimal likelihood of them failing to perform the required efforts for data collection. Each of the participants performed the two exercises in same order: bench press and then back squat, performing three lifts at each exercise against progressively increasing loads (40, 60 and 80 % 1RM). The individual's own body mass was factored into the back squat exercise, as this is a whole-body movement, but not into the bench press. The MuscleLab force-velocity linear encoder (Muscle Lab, Ergotest version 4010, Norway) was attached to an Eleiko Olympic bar (20 kg) which was set upon rests on a standard squat rack, safety arms were set so that the participant achieved ≤90° knee flexion position (settings measured and recorded during the familiarization process). From this position, the participant was instructed to drive the bar upwards as forcefully as possible; the value recorded during the test was for the concentric phase of the action only. The MuscleLab system encodes the force, the displacement of the bar, and the velocity produced for each individual lift, so that following measurements of muscle performance can be measured: average velocity (AV), average power (AP, average force x average velocity), peak velocity (PV, highest value of velocity), time to peak velocity (tPV, time to reach the highest value of velocity), mean propulsive velocity (MPV, average velocity during the propulsive phase of the concentric movement), rate of development of velocity (RDV, average acceleration during the propulsive phase of the concentric movement) and displacement (D, linear dis-placement of the bar during the movement). This process was repeated three times, with 5-min rest allowed between each individual lift, and against the progressive workloads as described above. For the bench press, the participant was instructed to descend the bar to their chest and, again, the instruction given was to push against the bar as forcefully as possible. This was repeated three times against the workloads described above, with 5-min rest between each push.
The highest of the three AP outputs (and associated AV, PV, MPV, RDV, D and tPV values) were used for analysis for each mass on the bar for both bench press and back squat, respectively. To reduce the likelihood of injury, two people were positioned either side of the participants as they performed their lifts, to intervene at any time if needed. In addition, there was safety support in place on every occasion.
Experimental Protocol and Measurements
The experimental sessions took place a week after the last familiarization with 72 h recovery between the three experimental conditions (i.e. CAFF, PLAC, NoPill). Upon arrival at the laboratory, they were asked to insert a soft flexi-ble rectal probe (mini-thermistor, Grant Instruments, Shepreth, UK) approximately 10 cm beyond the external anal sphincter. Participants then rested for 30 min in seated position to assess resting rectal temperature (Trec). Skin temperature (Tsk) was assessed simultaneously by skin thermistors (Grant Instruments, Squirrel 2010 series, Shepreth, UK), which were placed at four locations on the left side of the body (chest [ch], forearm [f], thigh [th] and calf [ca]). The average of the last 5 min of the 30 min resting period was recorded for resting Trec and Tsk temperatures. Mean Tsk was calculated as follows:
Tsk = (0.34 x Tch) + (0.33 x Tth) + (0.18 x Tca) + (0.15 x Tf)
The mean body temperature (Tmb) was calculated using:
Tmb = (0.64 x Tr) + (0.36 x Tsk).
Participants completed profile of mood states questionnaire (POMS; Version 32), their subjective rating of sleep (using sleep questions from the Liverpool Jet lag Questionnaire, effort (0-10, 0 = no effort and 10 = maximal effort) and rating of perceived exertion (RPE). After the initial rest measurements, participants warmed up on a cycle ergometer (Corival cpet, Lode, Groningen, Netherlands) for 5 min at 150 W. Post warm-up, participants removed rectal probes in private and skin thermistors were taken off. After which, MVC and bench press and back squat exercises were then undertaken.
Statistical analysis The main research variables in the present study were peak force in the MVC and PV in the bench press and back squat. For MVC peak force sixteen participants were estimated to provide 80% statistical power (p < 0.05), diurnal variation effect size (ES) of 0.67 for one tailed t-test. For PV for bench press nine participants were estimated to provide 80% statistical power (p < 0.05), diurnal variation effect size (ES) of 0.92 for one tailed t-test. For PV for back squat nine participants were estimated to provide 80% statistical power (p < 0.05), diurnal variation effect size (ES) of 0.91 for one tailed t-test. The investigators recruited 18 participants to allow for a dropout, with n=4 unable to complete the full protocol. The sample size estimation was performed using software G*Power 3.1. Data were analysed using the Statistical Package for Social Sciences version 30 (SPSS, Chicago, IL, USA). All data were checked for normality using the Shapiro-Wilk test. General linear models were used to analyse all measurements collected; the significance of interactions and main effects were evaluated by ANOVA. Sphericity violations were corrected by Greenhouse-Geisser (ε < 0.75) or Huynh-Feldt (ε > 0.75) and main effects by Bonferroni pairwise comparisons. Pearson correlations were conducted to explore individualized responses to CAFF vs other conditions (relative to body mass) and % change in MVC performance. All data is presented as means ± standard deviation (SD), unless otherwise stated. Significance was set at p ≤ 0.05. P values between 0.05 and 0.10 were considered to indicate a statistical trend. Effect sizes are referred to as partial eta squared values (η2p) with values of 0.01, 0.06 and 0.14 corresponding to a small, medium and large effect respectively. Ninety-five percent confidence intervals (95% CI) and mean differences between pairwise comparisons are reported where suitable.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
- Model description
- Double blinded counterbalanced design with three conditions
| Arm | Type | Receives |
|---|---|---|
| Group 1 | Experimental | Drug: 300mg of of caffeine anhydrous in 3 capsules similar to PLACEBO in size and weight, Other: Placebo, Dietary Supplement: No Pill1) NoPill, 2) PLAC, 3) Caffeine (300 mg) |
| Group 2 | Experimental | Drug: 300mg of of caffeine anhydrous in 3 capsules similar to PLACEBO in size and weight, Other: Placebo, Dietary Supplement: No Pill1) PLAC, 2) Caffeine (300 mg), 3) NoPill |
| Group 3 | Experimental | Drug: 300mg of of caffeine anhydrous in 3 capsules similar to PLACEBO in size and weight, Other: Placebo, Dietary Supplement: No Pill1) Caffeine (300 mg), 2) NoPill, 3) PLAC |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Healthy adults
- 18-35 years old
- Injury-free
- ≥ 2 years of weight/strength training experience
- Not receiving any pharmacological treatment (including non-steroidal anti-inflammatory drugs, NSAIDs) throughout the study period
Key exclusion criteria (6 listed)
- Depressed mood (from the Beck depression inventory)
- Poor sleep quality (a Pittsburgh sleep quality index global score >5
- Recent shiftwork or travel across multiple time-zones
- 'Extreme' chronotype (assessed via the Composite Morningness Questionnaire
- Risk factors and/or symptoms of cardiovascular disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 300mg of of caffeine anhydrous in 3 capsules similar to PLACEBO in size and weight300mg of of caffeine anhydrous in 3 capsules similar to PLACEBO in size and weight | Drug | Group 1, Group 2, Group 3 |
| PlaceboDescription: 3 capsules of PLACEBO similar to caffeine condition in size and weight | Other | Group 1, Group 2, Group 3 |
| No PillNo capsules were given. | Dietary supplement | Group 1, Group 2, Group 3 |
Primary outcome
Morning peak force production (N) measured via the Biodex Isometric MVC, with and without percutaneous stimulation.
Time frame: From familiarisation to the final experimental session (~4 weeks)
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on morning peak force production (N) measured via the Biodex Isometric MVC, with and without percutaneous stimulation.
Muscle Lab force-velocity linear encoder morning average power (AP, W), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition).
Time frame: From familiarisation to the final experimental session (~4 weeks)
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on Muscle Lab force-velocity linear encoder morning average power (AP, W), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition). The individual's own body mass was factored into the back squat exercise, as this is a whole-body movement, but not into the bench press. The MuscleLab force-velocity linear encoder (Muscle Lab, Ergotest version 4010, Norway) was attached to an Eleiko Olympic bar (20 kg) which was set upon rests on a standard squat rack, safety arms were set so that the participant achieved ≤90° knee flexion position (settings measured and recorded during the familiarization process). From this position, the participant was instructed to drive the bar upwards as forcefully as possible; the value recorded during the test was for the concentric phase of the action only.
Morning average velocity (AV, m/s), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition).
Time frame: From familiarisation to the final experimental session (~4 weeks)
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on Muscle Lab force-velocity linear encoder morning average velocity (AV, m/s), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition). The individual's own body mass was factored into the back squat exercise, as this is a whole-body movement, but not into the bench press. The MuscleLab force-velocity linear encoder (Muscle Lab, Ergotest version 4010, Norway) was attached to an Eleiko Olympic bar (20 kg) which was set upon rests on a standard squat rack, safety arms were set so that the participant achieved ≤90° knee flexion position (settings measured and recorded during the familiarization process). From this position, the participant was instructed to drive the bar upwards as forcefully as possible; the value recorded during the test was for the concentric phase of the action only.
Morning peak velocity (PV, m/s), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition).
Time frame: From familiarisation to the final experimental session (~4 weeks)
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on Muscle Lab force-velocity linear encoder morning peak velocity (PV, m/s), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition). The individual's own body mass was factored into the back squat exercise, as this is a whole-body movement, but not into the bench press. The MuscleLab force-velocity linear encoder (Muscle Lab, Ergotest version 4010, Norway) was attached to an Eleiko Olympic bar (20 kg) which was set upon rests on a standard squat rack, safety arms were set so that the participant achieved ≤90° knee flexion position (settings measured and recorded during the familiarization process). From this position, the participant was instructed to drive the bar upwards as forcefully as possible; the value recorded during the test was for the concentric phase of the action only.
Morning mean propulsive velocity (MPV, m/s), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition).
Time frame: From familiarisation to the final experimental session (~4 weeks)
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on Muscle Lab force-velocity linear encoder morning mean propulsive velocity (MPV, m/s), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition). The individual's own body mass was factored into the back squat exercise, as this is a whole-body movement, but not into the bench press. The MuscleLab force-velocity linear encoder (Muscle Lab, Ergotest version 4010, Norway) was attached to an Eleiko Olympic bar (20 kg) which was set upon rests on a standard squat rack, safety arms were set so that the participant achieved ≤90° knee flexion position (settings measured and recorded during the familiarization process). From this position, the participant was instructed to drive the bar upwards as forcefully as possible; the value recorded during the test was for the concentric phase of the action only.
Morning rate of development of velocity (RDV), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition).
Time frame: From familiarisation to the final experimental session (~4 weeks)
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on Muscle Lab force-velocity linear encoder morning rate of development of velocity (RDV), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition). The individual's own body mass was factored into the back squat exercise, as this is a whole-body movement, but not into the bench press. The MuscleLab force-velocity linear encoder (Muscle Lab, Ergotest version 4010, Norway) was attached to an Eleiko Olympic bar (20 kg) which was set upon rests on a standard squat rack, safety arms were set so that the participant achieved ≤90° knee flexion position (settings measured and recorded during the familiarization process). From this position, the participant was instructed to drive the bar upwards as forcefully as possible; the value recorded during the test was for the concentric phase of the action only.
Morning displacement (D, cm), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition).
Time frame: From familiarisation to the final experimental session (~4 weeks)
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on Muscle Lab force-velocity linear encoder morning displacement (D, cm), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition). The individual's own body mass was factored into the back squat exercise, as this is a whole-body movement, but not into the bench press. The MuscleLab force-velocity linear encoder (Muscle Lab, Ergotest version 4010, Norway) was attached to an Eleiko Olympic bar (20 kg) which was set upon rests on a standard squat rack, safety arms were set so that the participant achieved ≤90° knee flexion position (settings measured and recorded during the familiarization process). From this position, the participant was instructed to drive the bar upwards as forcefully as possible; the value recorded during the test was for the concentric phase of the action only.
Morning time-to-peak velocity (tPV, m/s/s), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition).
Time frame: From familiarisation to the final experimental session (~4 weeks)
To assess the effect of 300 mg caffeine (CAFF) vs placebo (PLAC) vs no-pill (NoPill) on Muscle Lab force-velocity linear encoder morning time-to-peak velocity (tPV, m/s/s), for bench press and back squat at 40, 60 and 80% 1RM (maximum repetition). The individual's own body mass was factored into the back squat exercise, as this is a whole-body movement, but not into the bench press. The MuscleLab force-velocity linear encoder (Muscle Lab, Ergotest version 4010, Norway) was attached to an Eleiko Olympic bar (20 kg) which was set upon rests on a standard squat rack, safety arms were set so that the participant achieved ≤90° knee flexion position (settings measured and recorded during the familiarization process). From this position, the participant was instructed to drive the bar upwards as forcefully as possible; the value recorded during the test was for the concentric phase of the action only.
3 secondary outcomes
Morning Trail Making Test time to completion in seconds (TMT; parts A and B)
Time frame: From enrolment to last experimental session (4 weeks)
Morning Rey Auditory Verbal Learning Test
Time frame: From familiarisation to the final experimental session (~4 weeks)
Morning Stroop word-color interference test
Time frame: From familiarisation to the final experimental session (~4 weeks)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Mar 2026.
- Background: PubMed 1365645Mitchell PJ, Redman JR. Effects of caffeine, time of day and user history on study-related performance. Psychopharmacology (Berl). 1992;109(1-2):121-6. doi: 10.1007/BF02245489.
- Background: PubMed 33345139Martins GL, Guilherme JPLF, Ferreira LHB, de Souza-Junior TP, Lancha AH Jr. Caffeine and Exercise Performance: Possible Directions for Definitive Findings. Front Sports Act Living. 2020 Dec 11;2:574854. doi: 10.3389/fspor.2020.574854. eCollection 2020.
- Background: PubMed 37589927Munnilari M, Bommasamudram T, Easow J, Tod D, Varamenti E, Edwards BJ, Ravindrakumar A, Gallagher C, Pullinger SA. Diurnal variation in variables related to cognitive performance: a systematic review. Sleep Breath. 2024 Mar;28(1):495-510. doi: 10.1007/s11325-023-02895-0. Epub 2023 Aug 17.
- Background: PubMed 38722075Robertson CM, Pullinger SA, Robinson WR, Smith ME, Burniston JG, Edwards BJ. Circadian variation in muscle force output in males using isokinetic, isometric dynamometry: can we observe this in multi-joint movements using the muscleLab force-velocity encoder and are they similar in peak and magnitude? Chronobiol Int. 2024 May;41(5):709-724. doi: 10.1080/07420528.2024.2348011. Epub 2024 May 9.
- Background: PubMed 15865319Drust B, Waterhouse J, Atkinson G, Edwards B, Reilly T. Circadian rhythms in sports performance--an update. Chronobiol Int. 2005;22(1):21-44. doi: 10.1081/cbi-200041039.
- Background: PubMed 33144349Walsh NP, Halson SL, Sargent C, Roach GD, Nedelec M, Gupta L, Leeder J, Fullagar HH, Coutts AJ, Edwards BJ, Pullinger SA, Robertson CM, Burniston JG, Lastella M, Le Meur Y, Hausswirth C, Bender AM, Grandner MA, Samuels CH. Sleep and the athlete: narrative review and 2021 expert consensus recommendations. Br J Sports Med. 2020 Nov 3:bjsports-2020-102025. doi: 10.1136/bjsports-2020-102025. Online ahead of print.
- Individual participant dataSharing planned: No. IPD unavailable due to privacy or ethical restrictions
Related trials for Caffine
Active, not recruitingPhase 1/2
Effects of Caffeine Ingestion on Morning Cognitive and 4-km Time Trial Performance in Males
Caffeine, Placebo - Control
Enrolling by invitationEarly Phase 1
Effects of Caffeine Ingestion on Morning Cognitive and Muscle Repeated Sprint Performance in Males
Caffeine, Placebo - Control
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ben J Edwards, PHD principal investigator
Liverpool John Moores University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing No Pill in people with Caffine and Placebo - Control, run by Liverpool John Moores University at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Morning peak force production (N) measured via the Biodex Isometric MVC, with and without percutaneous stimulation. (time frame: From familiarisation to the final experimental session (~4 weeks)). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07466628, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2026.